Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Are Investors Showing Interest in Agronomics Right Now?

Introduction: What Triggered the Rise in ANIC Stock?

Ankur Sharma | 01 May 2026

Can Drug Development Progress Boost ImmuPharma Stock Further?

Introduction: What Triggered the Rise in IMM Stock?

Ankur Sharma | 01 May 2026

Is the Fall in Shield Therapeutics a Buying Opportunity or a Warning Sign?

Introduction: What Triggered the Drop in STX Stock?

Ankur Sharma | 01 May 2026

Why Are Pharma Stocks Like AstraZeneca Falling Despite Defensive Demand?

Why Is LSE:AZN – AstraZeneca Stock Trading Down Today on 1 May 2026 Despite Strong Fundamentals?

Ankur Sharma | 01 May 2026

Is LSE:FUM Facing a Biotech Sector-Wide Correction or Company-Specific Risk?

Why Is LSE:FUM – Futura Medical Stock Falling 16.8% Today?

Ankur Sharma | 30 April 2026

Will Diagnostics Innovation Drive Novacyt’s Next Growth Phase?

Novacyt S.A.is an international diagnostics and biotechnology company focused on developing and supplying molecular diagnostic solutions for infectious diseases, oncology, and clinical testing.

Ishan Mudgal | 30 April 2026

Can NIOX Benefit from the Global Growth in Asthma Diagnostics?

Following its strategic transformation from a broader diagnosticsBusinessinto a focused respiratory diagnostics specialist, NIOX has emerged with a sharperInvestmentnarrative centred on a single, growing addressable market. The recent share price strength suggests that more investors are taking a closer look at this story.

Ankur Sharma | 30 April 2026

Is Genus a Hidden Long-Term Growth Story in Animal Genetics?

The wider animal genetics and agricultural biotech sector has been navigating a complex environment, including pricing pressures in pork markets, regulatory developments around gene-edited livestock and broader caution toward UK growth equities. These factors have combined to weigh on sentiment.

Ankur Sharma | 30 April 2026

Can GSK Deliver Stronger Returns After Its Strategic Reset?

The recent share price strength comes against a backdrop of stronger commercial performance in keyVaccineand specialty pharmaceutical franchises, ongoing R&D pipeline progression and a clearer focus following the demerger of consumer healthcareBusinessHaleon. Investors are evaluating whether GSK's strategic transformation is now bearing fruit.

Ankur Sharma | 30 April 2026

Is Convatec a Hidden Defensive Growth Stock in the FTSE 100?

The recent share price strength comes after a period in which medical device names globally have been weighed down by concerns about valuation multiples, the impact of GLP-1 weight-loss drugs on certain device categories and broader macro uncertainty. With CTEC.L trading at levels that …

Ankur Sharma | 30 April 2026

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions